What are pharmacogenomic biomarkers?

PHARMACOGENOMIC GERMLINE BIOMARKERS Pharmacogenomic biomarkers are mostly located in genes encoding drug-metabolizing enzymes, transporters, drug targets, or HLA alleles and predict drug efficacy or inform about the risk to develop ADRs (Tables 2 and 3).

What are pharmacogenomic tests?

Pharmacogenomic tests look for changes or variants in these genes that may determine whether a medication could be an effective treatment for you or whether you could have side effects to a specific medication.

What is the first line drug therapy for hypertension?

There are three main classes of medication that are usually in the first line of treatment for hypertension: 1. Calcium Channel Blockers (CCB) 2. Angiotensin Converting Enzyme inhibitors (ACE inhibitors or ACE-I) and Angiotensin Receptor Blockers (ARBs) 3. Diuretics.

How accurate is pharmacogenomic testing?

Only 36% of the labels reviewed provided convincing evidence for the clinical validity of the pharmacogenetic test, that is, an established association between the pharmacogenetic variant and drug response; and only 15% provided convincing evidence of clinical utility, that is, one or more controlled studies …

How is pharmacogenomic testing done?

What happens during a pharmacogenetic test? Testing is usually done on blood or saliva. For a blood test, a health care professional will take a blood sample from a vein in your arm, using a small needle. After the needle is inserted, a small amount of blood will be collected into a test tube or vial.

What is pharmacogenomic data?

Pharmacogenomics is the study of how genes affect a person’s response to drugs. This field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications that can be prescribed based on a person’s genetic makeup.

What is the main objective of pharmacogenomic studies?

Pharmacogenomics (sometimes called pharmacogenetics) is a field of research that studies how a person’s genes affect how he or she responds to medications. Its long-term goal is to help doctors select the drugs and doses best suited for each person.

What are the limitations of pharmacogenomics?

Particular limitations for pharmacogenetic GWA studies include small sample sizes due to rare adverse drug reactions and the difficulty of replication, lack of rare or even less common (<5%) variants on the microarrays, and heterogeneity of drug response phenotype.

How much does a pharmacogenetic test cost?

Treatment response rates, mortality rates, direct and indirect medical costs, and utility inputs were derived from the reference study and published scientific literature. The cost of the pharmacogenetic test was $2,000. A 3% discount rate was used to discount costs and effects.

When is pharmacogenomics used?

Pharmacogenomics is an important example of the field of precision medicine, which aims to tailor medical treatment to each person or to a group of people. Pharmacogenomics looks at how your DNA affects the way you respond to drugs.

What kind of benefits will be gained in the terms of patient approach by pharmacogenomic tests?

Pharmacogenomics eventually can lead to an overall decrease in the cost of health care because of decreases in: (1) the number of adverse drug reactions; (2) the number of failed drug trials; (3) the time it takes to get a drug approved; (4) the length of time patients are on medication; (5) the number of medications …

What is the safest BP medicine?

Methyldopa, which works to lower blood pressure through the central nervous system, has the lowest risk of harming the mother and developing fetus. Other possible safe options include labetalol, beta-blockers, and diuretics.

Which is better amlodipine or losartan?

In this study amlodipine proved to be more effective than losartan in achieving the primary end point of reducing mean sitting and standing diastolic and systolic blood pressures, although there was no difference in the percentages of each drug in who reached goal pressure at the initial dosages.

Is pharmacogenomic testing covered by insurance?

The coverage of pharmacogenetic tests varied widely among companies. Overall, evidence-driven and medically recommended pharmacogenetic tests are not consistently available or covered by private health insurance companies, potentially impacting patients’ health outcomes.

Who should get pharmacogenetic testing?

Who is PGx testing best suited for?

• People worried about developing side effects to medicines or those who already have had significant side effects to past trials of psychiatric medicines.
• People with comorbidities (co-occurring conditions): Treating one psychiatric condition is a challenge on its own.

What are the limitations of pharmacogenomics of hypertension?

The inconsistencies and limitations observed in studies of pharmacogenomics of hypertension may be also dependent on the type of strategy applied. In fact, vast majority of studies discussed here applied two different approaches: gene candidate and GWAS. During the past decade, the shift from gene candidate approach to GWAS has been noteworthy.

What are the guidelines for the treatment of hypertension (high blood pressure)?

• Lifestyle changes are recommended (smoking cessation, diet and exercise). • BP should be lowered if ≥140/90 mmHg and treated to a target <130/80 mm Hg (<140/80 in elderly patients). • RAS blockers, beta-blockers irrespective of BP levels with or without calcium channel blockers (CCBs) are first-line drugs in hypertensive patients.1

Is there a role for gene-gene interactions in hypertension pharmacogenomics?

More recently, a third approach that considers gene-gene interactions has also been applied in hypertension pharmacogenomics.

What are the ish global hypertension practice guidelines 1351?

Unger et al 2020 ISH Global Hypertension Practice Guidelines 1351 the EASD: The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). [Cosentino F, Peter J, Grant PJ, Aboyans V et al. Eur Heart J2020; 41:255–323,